Condition: Brain Metastasis From Advanced HER2-negative Breast Cancer · Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Prospective, multicenter, randomized controlled phase II study to evaluate the efficacy and safety of PD-L1 monoclonal antibody combined with vinorelbine + cyclophosphamide + capecitabine (VEX) metronomic chemotherapy and concurrent or delayed radiotherapy in patients with advanced HER2-negative breast cancer with brain metastasis
This description comes directly from the study's public registry record.
飞 马 · 13910217780 · drmafei@126.com
Always discuss trial participation with your own doctor first.
| Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing 100021 | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06839560